News
2h
Zacks Investment Research on MSNExelixis Gains 15.6% YTD: How Should You Play the Stock?
Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...
Even some of the S&P 500's (SNPINDEX: ^GSPC) seemingly safe dividend stocks have been upended, even if only because so many ...
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...
Cowboys owner Jerry Jones revealed he quietly battled stage 4 melanoma for over a decade, crediting experimental ...
Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results